Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays Leukemia (2005) Within the spectrum of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL) is a distinct entity, based not only on its biological characteristics but also on its unique pattern of genetic features.
1 PMBL appears to be more similar to classical Hodgkin's lymphoma (cHL) than DLBCL; both exhibit common genetic changes including amplification of chromosome 2p13 and 9p24 as well as similar gene expression profiles. [2] [3] [4] In chromosome 9p24, JAK2 has been considered as a candidate oncogene, based on recent studies revealing high JAK2 transcription 2,4 and constitutive phosphorylation in PMBL. 5 In a recent report In 'Blood', Melzner et al 6 confirmed that in the MedB-1 mediastinal B-cell line, which harbors a gain of 9p24, JAK2 transcription was elevated and the product was highly phosphorylated. Notably, JAK2 protein was not overexpressed and protein turnover delayed. This unexpected finding coincided with a biallelic mutation of the SOCS1 gene, which abrogated SOCS box function of the protein. Ectopic expression of wild-type SOCS1 in MedB-1 lead to growth arrest, reduction of phospho-JAK2 and its downstream partner phospho-STAT5. The authors concluded that action of phospho-JAK2 was sustained due to defective SOCS1. Further investigation revealed SOCS1 mutation in nine of 20 PMBL primary samples, seven of which also showed genomic gain of 9p24/ JAK2 locus.
We compared the genomic patterns of 43 B-cell non-Hodgkin lymphoma (B-NHL) cell lines of different origins using CGH to a microchip with B2400 BAC clones covering the genome.
7 In this analytical model, we also investigated the level of expression of the genes mapped across aberrant chromosome regions using the 'Lymphochip' cDNA microarrays. 8 Array CGH analysis detected homozygous deletion of BAC RP11-49M6 (which overlaps BAC-574D14) in band 16p13.13 in the Karpas 1106 cell line, derived from a patient with PMCL ( Figure 1 ).
9
Color cytogenetic analysis revealed two apparently normal copies of chromosome 16. Karpas 1106 also showed two-fold amplification of 9p24 including JAK2. Genomic PCR analyses delineated the region of loss to B700 kb of genomic sequence including the full SOCS1 gene. Gene expression microarrays revealed absence of expression of SOCS1, which was consistent with genomic PCR analyses (data not shown). Array CGH analysis of 42 other B-NHL cell lines and of 112 primary B-NHL samples, none of which were classified as PBML, identified monoallelic deletion of SOCS1 locus in only one patient with mantle cell lymphoma.
Initial analysis revealed allelic loss of SOCS1 locus in half of hepatocellular carcinomas. Subsequent studies have identified aberrant methylation in the CpG island of SOCS1 that correlates with its transcription silencing in most carcinomas and hematological malignancies. 10 In addition, monoallelic deletion of SOCS1 with convergent hypermethylation of the remaining allele is also common. Confirming Dr Melzner's report, we have found a novel mechanism of SOCS1 inactivation by biallelic CGH to BAC microarrays pinpoints biallelic deletion of SOCS1 in the Karpas 1106 cell line. Map of chromosome 16p13.13 including the clones used for narrowing down the commonly deleted interval by array CGH, FISH and genomic PCR. Array CGH analysis in chromosome 16 showed homozygous deletion of clone RP11-49M6, which overlaps with RP11-574D14. Additional FISH analysis showed homozygous deletion of clone RP11-396B14, not included into the array. FISH studies of clone RP11-66H6 at the centromeric border of the deletion corresponded to one copy, whereas BAC RP11-394B14 delineated the telomeric border, showing values corresponding to two copies. Genomic PCR analyses confirmed FISH and array CGH data (data not shown). Emerging preclinical and clinical data suggest that T cells recognize and kill malignant cells in patients with hematological malignant disorders. The lower rates of relapse in the setting of allogeneic transplantation compared with those in autologous bone marrow transplantation, the striking clinical benefit of donor-lymphocyte infusions as well as the finding that human T cells can destroy chemotherapy-resistant cell lines from chronic myeloid leukemia and multiple myeloma, have prompted development of immunotherapeutic strategies against hematological cancers. 1 Among these approaches, active specific immunization or vaccination is emerging as a valuable tool to boost the adaptive immune system against malignant cells. In this regard, the identification of leukemia-associated antigens is crucial. However, very few antigens are characterized in a conceptual framework in which the biology, microenvironment, and conventional disease management have been taken into consideration. The antiapoptotic protein Mcl-1 plays an important role in cancer as it has been directly linked to resistance to conventional forms of therapies and poor prognosis.
2 Accordingly, downregulation of Mcl-1 would severely inflict the survival capacity of tumor cells, which highlights this protein as a prime candidate as vaccination target in therapeutic vaccinations against cancer, since it is not subject to immune selection as well as it would synergistically boosts the effects of conventional cytotoxic therapies. Recently, we demonstrated that cancer patients of different origin host spontaneous T-cell responses specifically against Mcl-1-derived peptides presented in the context of the HLA-A3 antigen.
3 In the present study, the amino-acid sequence of the Mcl-1 protein was screened for the most probable HLA-A1 nona-and decamer peptide epitopes, using the main HLA-A1-specific anchor residues.
4 Four Mcl-1 deduced peptides (Mcl-1(166-175) (PAEEEEDDLY), Mcl-1(121-129) (SPEEELDGY), Mcl-1(177-185) (QSLEIISRY), and Mcl-1(339-347) (AGVGAGLAY) were synthesized and examined for binding to HLA-A1 by comparison with the HLA-A1 high-affinity positive control epitope from influenza PBI(591-599) (VSDGGPNLY) (Figure 1 ). Only the peptide Mcl-1(177-185) bound with almost similar high affinity as the positive control (Figure 1a) , whereas the three additional PBL from seven healthy individuals, five patients with CLL, six melanoma patients, and four patients with breast cancer were examined. All individuals were HLA-A1 positive. The average number of peptide-specific spots (after subtraction of spots without added peptide) was calculated for each patient using the ImmunoSpot
